Trial Condition(s):

Multiple Sclerosis

Depression and fatigue in MS patients treated with Betaferon. (FADO)

Bayer Identifier:

15307

ClinicalTrials.gov Identifier:

NCT01354665

EudraCT Number:

Not Available

Study Completed

Trial Purpose

This study aims to evaluate the occurence and severity of fatigue and depression in multiple sclerosis patients and the impact of Betaferon treatment on symptoms alterations.
The study is conducted in routine practice setting hence no interference with standard care takes place.
Pharmacologic treatments of MS-fatigue and depression will also be recorded.

Inclusion Criteria
- Relapsing-remitting multiple sclerosis
  - Age 18+
  - Patients initiating Betaferon treatment
Exclusion Criteria
- Patients previously treated with any immunomodulatory drug

Trial Summary

Enrollment Goal
567
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Betaseron (Interferon beta-1b, BAY86-5046)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, Poland

Status
Completed
 

Trial Design